Inspra (eplerenone) is a steroid nucleus-based mineralcorticoid receptor (MR) antagonist with a higher degree of selectivity than spironolactone. In the Phase 3B, multinational, randomized, double-blind placebo-controlled, parallel-group trial,
The CHMP has recommended to grant the marketing authorization for Vibativ (telavancin hydrochloride) as a treatment for adults who are suffering from nosocomial pneumonia with ventilator-associated pneumonia, known
The new patent entitled ‘Polyoxazoline and compositions comprising the same,’ covers the synthesis and composition of polyoxazolines for the delivery of different drug molecules. Serina chief scientific officer
SUTENT is an oral multi-kinase inhibitor that works by blocking multiple molecular targets implicated in the growth, proliferation and spread of cancer. The FDA approval is based on
The completed integration is expected to enable the rapid transfer of Phase I data and metadata collected in ALPHADAS into Medidata Rave. ALPHADAS is a multi-study, schedule-driven, automated
The CHMP has recommended the marketing authorization of Benlysta as an add-on therapy in adult patients who are suffering from active autoantibody-positive systemic lupus erythematosus, with a high
The data demonstrated statistical prominence in every category analyzed, with only very minor and minimal adverse events. The study involved around 604 intent-to-treat patients. On the basis of
The approval is based on the ADVANCE-2 and ADVANCE-3 clinical trials, part of the EXPANSE clinical trial program. ELIQUIS is an oral anticoagulant with a 12- to 24-hour
PinAAcle series’ configuration allows for compact design in applications like environmental regulations for drinking water, clinical usage in customer-validated applications such as screening for lead, and requirements of
The latest facility is one of a network of six global RD&I centers that work with the company’s businesses . The six global RD&I centers host a combination
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.